Financial Report: Wyeth 2Q

Wyeth 

2Q Revenues: $5.9 billion (+5%)
 
2Q Earnings: $1.1 billion (-6%)

YTD Revenues: $11.7 billion (+6%)

YTD Earnings: $2.3 billion (-5%)

Comments: Pharmaceutical sales were $5.0 billion (+5%), due to Effexor, Enbrel, Prevnar, and Zosyn sales, as well as the favorable foreign exchange, offset, in part, by lower sales of Protonix due to generic competition. Effexor sales in the quarter were $1.0 billion (+5%) and $2.0 billion YTD (+9%). Prevnar sales were $691 million (+9%) and $1.4 billion YTD (+12%). Enbrel revenues in the quarter were $976 million and $1.9 billion YTD, which includes sales outside U.S. and Canada (+36% 2Q and YTD) and alliance revenue in the U.S. and Canada (+6% 2Q and 23% YTD). Zosyn/Tazocin sales were $319 million (+14%) in the quarter and $661 million YTD (18%). R&D expenses (excluding impact of foreign exchange) were $836 million in the quarter (+1%) and $1.7 billion YTD (+6%).